Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Batist

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1992
Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activityM A Alaoui-Jamali, L Panasci, G M Centurioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical modulation of glutathioneX Chen, R L Schecter, O W Griffith, et al.
Toxicologic Pathology|July 1, 1996
Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitisG M Kirby, G Batist, L Alpert, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1996
Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor responseT Wang, X Chen, R L Schecter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levelsG Batist, F Patenaude, P Champagne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, P Hoskins, G Stuart, et al.
Mutation Research|May 1, 1995
Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistanceJ Bramson, A McQuillan, R Aubin, et al.
Molecular Pharmacology|August 1, 1989
Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell lineG Batist, S Torres-Garcia, J M Demuys, et al.
Molecular Pharmacology|September 1, 1990
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cellsV Skalski, D B Yarosh, G Batist, et al.
The Journal of Biological Chemistry|November 25, 1986
Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cellsG Batist, A Tulpule, B K Sinha, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|January 1, 1992
Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activityM A Alaoui-Jamali, L Panasci, G M Centurioni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical modulation of glutathioneX Chen, R L Schecter, O W Griffith, et al.
Toxicologic Pathology|July 1, 1996
Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitisG M Kirby, G Batist, L Alpert, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1996
Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor responseT Wang, X Chen, R L Schecter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levelsG Batist, F Patenaude, P Champagne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, P Hoskins, G Stuart, et al.
Mutation Research|May 1, 1995
Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistanceJ Bramson, A McQuillan, R Aubin, et al.
Molecular Pharmacology|August 1, 1989
Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell lineG Batist, S Torres-Garcia, J M Demuys, et al.
Molecular Pharmacology|September 1, 1990
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cellsV Skalski, D B Yarosh, G Batist, et al.
The Journal of Biological Chemistry|November 25, 1986
Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cellsG Batist, A Tulpule, B K Sinha, et al.
Pageof 12